Businesses should look "to convey a superior product or an additional motivation to buy the alternative", GlobalData says.
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NMD Pharma’s oral lead development programme, NMD670, designed to treat Charcot-Marie-Tooth disease (CMT). A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback